Recombinant COVID-19 vaccine(CHO cell)
Phase 2Vaccine
Recombinant COVID-19 vaccine(CHO cell) is one of 64 biologic programs targeting Pneumonia. It is currently in Phase 2.
2
Indications
15
Total Trials
1
Active Trials
63
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Spikevax
ModernaPreclinical
Bnt162b2
BioNTechPreclinical
COVID-19 Vaccine
ModernaPreclinical
Recombinant COVID-19 vaccine(CHO cell)
WWestVac Biopharma Co., Ltd.
Phase 2
Biaxin
AbbViePreclinical
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Singulair
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
COVID-1913 trials
Show 10 more trials
Pneumonia1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Phase 2[1]
- Company
- WWestVac Biopharma Co., Ltd.